Literature DB >> 20921340

Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells.

Korashon L Watts1, Colleen Delaney, R Keith Humphries, Irwin D Bernstein, Hans-Peter Kiem.   

Abstract

Umbilical cord blood (UCB) is an attractive cell source for hematopoietic cell transplantation (HCT). Here we examine whether the combination of homeobox B4 (HOXB4) and Delta-1 ligand (DL) synergize when used together. Monkey and human UCB CD34(+) cells were transduced with a HOXB4-expressing gammaretroviral vector and cultured with DL. Individual and combined effects of HOXB4 and DL were assessed by colony-forming unit assays, flow cytometry, and nonobese diabetic/severe combined immune deficienct mouse transplantation. The presence of DL yielded higher percentage of CD34(+) and CD7(+) cells and lower percentages of CD14(+) cells than non-DL cultures. Furthermore, HOXB4 yielded higher percentages of CD34(+) and CD14(+) cells than non-HOXB4 cultures. Interestingly, coculture with DL-expressing OP9 cells resulted in better maintenance of HOXB4 than culture in DL-conditioned medium. Culture of HOXB4-transduced human cells in the presence of DL yielded enhanced generation of repopulating cells with higher levels of engraftment of human CD45(+), CD34(+), CD3(+), CD20(+), and CD41(+) cells compared with either factor individually. Our results demonstrate enhanced generation of hematopoietic progenitors by combining HOXB4 and DL; addition of DL further enhances expansion of multipotent cells capable of repopulating lymphoid and megakaryocyte lineages, which is not observed with HOXB4 alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921340      PMCID: PMC3031382          DOI: 10.1182/blood-2010-05-286062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Regulation of T cell fate by Notch.

Authors:  E Robey
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells.

Authors:  Tobias Neff; Laura J Peterson; Julia C Morris; Jesse Thompson; Xiaobing Zhang; Peter A Horn; Bobbie M Thomasson; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2004-02       Impact factor: 11.454

3.  Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells.

Authors:  Yue Zhang; Chou Chai; Xue-Song Jiang; Swee-Hin Teoh; Kam W Leong
Journal:  Tissue Eng       Date:  2006-08

4.  Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood.

Authors:  A L Pecora; P Stiff; A Jennis; S Goldberg; R Rosenbluth; P Price; K L Goltry; J Douville; R D Armstrong; A K Smith; R A Preti
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

5.  Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors.

Authors:  R G Andrews; J W Singer; I D Bernstein
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

6.  Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells.

Authors:  Colleen Delaney; Barbara Varnum-Finney; Keisuke Aoyama; Carolyn Brashem-Stein; Irwin D Bernstein
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

7.  Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity.

Authors:  Na Li; Pierre Feugier; Brigitte Serrurrier; Veronique Latger-Cannard; Jean-François Lesesve; Jean-François Stoltz; Assia Eljaafari
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

8.  Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro.

Authors:  Ross N La Motte-Mohs; Elaine Herer; Juan Carlos Zúñiga-Pflücker
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

9.  Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.

Authors:  Eliane Gluckman; Vanderson Rocha; William Arcese; Gérard Michel; Guillermo Sanz; Ka-Wah Chan; Tsuneo A Takahashi; Juan Ortega; Alexandra Filipovich; Franco Locatelli; Shigetaka Asano; Franca Fagioli; Marcus Vowels; Anne Sirvent; Jean-Philippe Laporte; Karin Tiedemann; Sergio Amadori; Manuel Abecassis; Pierre Bordigoni; Blanca Diez; Peter J Shaw; Ajay Vora; Maurizio Caniglia; Federico Garnier; Irina Ionescu; Joan Garcia; Gesine Koegler; Paolo Rebulla; Sylvie Chevret
Journal:  Exp Hematol       Date:  2004-04       Impact factor: 3.084

10.  In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein.

Authors:  Jana Krosl; Pamela Austin; Nathalie Beslu; Evert Kroon; R Keith Humphries; Guy Sauvageau
Journal:  Nat Med       Date:  2003-10-26       Impact factor: 53.440

View more
  17 in total

1.  Gene therapy for Fanconi anemia: one step closer to the clinic.

Authors:  Jakub Tolar; Pamela S Becker; D Wade Clapp; Helmut Hanenberg; Cristina Díaz de Heredia; Hans-Peter Kiem; Susana Navarro; Pankaj Qasba; Paula Rio; Manfred Schmidt; Julián Sevilla; Els Verhoeyen; Adrian J Thrasher; Juan Bueren
Journal:  Hum Gene Ther       Date:  2012-02       Impact factor: 5.695

Review 2.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

Review 3.  Concise review: ex vivo expansion of cord blood-derived hematopoietic stem and progenitor cells: basic principles, experimental approaches, and impact in regenerative medicine.

Authors:  Patricia Flores-Guzmán; Verónica Fernández-Sánchez; Hector Mayani
Journal:  Stem Cells Transl Med       Date:  2013-10-07       Impact factor: 6.940

4.  Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification.

Authors:  Melanie G Cornejo; Vinciane Mabialah; Stephen M Sykes; Tulasi Khandan; Cristina Lo Celso; Cécile K Lopez; Paola Rivera-Muñoz; Philippe Rameau; Zuzana Tothova; Jon C Aster; Ronald A DePinho; David T Scadden; D Gary Gilliland; Thomas Mercher
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  HOXA4 provides stronger engraftment potential to short-term repopulating cells than HOXB4.

Authors:  Marilaine Fournier; Charles-Étienne Lebert-Ghali; Janetta J Bijl
Journal:  Stem Cells Dev       Date:  2015-08-12       Impact factor: 3.272

Review 6.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

7.  CD34(+) expansion with Delta-1 and HOXB4 promotes rapid engraftment and transfusion independence in a Macaca nemestrina cord blood transplant model.

Authors:  Korashon L Watts; Colleen Delaney; Veronica Nelson; Grant D Trobridge; Brian C Beard; R Keith Humphries; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

8.  Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation.

Authors:  Alice M S Cheung; Donna Leung; Shabnam Rostamirad; Kiran Dhillon; Paul H Miller; Radina Droumeva; Ryan R Brinkman; Donna Hogge; Denis Claude Roy; Connie J Eaves
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

Review 9.  Notch signaling in hematopoietic cell transplantation and T cell alloimmunity.

Authors:  Christen L Ebens; Ivan Maillard
Journal:  Blood Rev       Date:  2013-08-31       Impact factor: 8.250

10.  Hematopoietic stem cell expansion facilitates multilineage engraftment in a nonhuman primate cord blood transplantation model.

Authors:  Korashon L Watts; Veronica Nelson; Brent L Wood; Grant D Trobridge; Brian C Beard; R Keith Humphries; Hans-Peter Kiem
Journal:  Exp Hematol       Date:  2011-12-08       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.